Boston area CRO Integral BioSystems, LLC announces Expanded Formulation Development Facilities

Boston area based CRO Integral BioSystems, LLC offers formulation development expertise, particularly in the development of ophthalmics, parenterals, dermals and oral dosage forms. Additionally, the company offers patent services.
 
June 12, 2010 - PRLog -- Integral BioSystems, a contract research organization in the Boston area announced today to the Biotech community that it has expanded its facilities in formulation development, with the recent addition of a state-of-the-art Mass Spectrometer and a fully equipped microencapsulation laboratory.

The company offers microsphere encapsulation for small molecule drugs and specializes in the design and development of dosage forms for ophthalmic, transdermal, intravenous, intranasal and oral routes of drug administration. Additionally, the company offers analytical method development and intellectual property and contracts development/negotiation services.

“Integral BioSystems excels in the conceptualization and design of drug development solutions for drug candidates that are challenging to deliver. These challenges include inherent insolubility of the drug, intrinsic tissue impermeability of the drug, and incompatibility with physiological fluids.  Our services also include the development of sustained release systems, such as microspheres, nanospheres, liposomes, depots, etc.  We hope to form liaisons and collaborations with start-ups and larger companies alike,” said Mr. Karasic, Chief Intellectual Property Officer of Integral BioSystems, LLC.

# # #

About Integral BioSystems, LLC

Integral BioSystems, LLC was founded by experienced drug development and patent professionals. The company has adopted a translational medicinal approach to drug development, customizing delivery systems to accomplish the biologically effective objectives of the therapy. Delivery systems are customized to achieve targeted, tissue-focused delivery depending upon the desired product attributes.
Once the drug-containing formulations are tested in preclinical models, an integrated CMC plan is developed to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept. The company has a network of manufacturers / analytical houses for pharmaceutics, that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.
End
Integral BioSystems, LLC News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share